Meeting
2024 ASCO Annual Meeting
The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.
Authors
Mengni Guo
Department of Oncology/Hematology, Loma Linda University Medical Center, Loma Linda, CA
Mengni Guo , Zohaib Ahmed , Phuong Nguyen , Kashaf Zaidi , Raphael Itzkowitz , Esther G Chong , Dani Ran Castillo , Huynh Le Cao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2648)
DOI
10.1200/JCO.2024.42.16_suppl.2648
Abstract #
2648
Poster Bd #
127
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).
First Author: Ragisha Gopalakrishnan
Poster
2018 ASCO Annual Meeting
Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
First Author: Leena Gandhi
Poster
2024 ASCO Annual Meeting
Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.
First Author: Alexander Frey
Poster
2024 ASCO Genitourinary Cancers Symposium
Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer.
First Author: Jonathan Forrest Anker